Literature DB >> 26537525

The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV.

Julia Thornton Snider1, Dana P Goldman2, Lisa Rosenblatt3, Daniel Seekins3, Timothy Juday4, Yuri Sanchez4, Yanyu Wu5, Desi Peneva5, John A Romley2.   

Abstract

We investigated the effect of changes to state AIDS Drug Assistance Programs (ADAP) policies, which govern access to antiretroviral therapy (ART), on clinical and economic outcomes among low-income people living with HIV/AIDS. Retrospective analyses of ART access were conducted on state ADAP policies, using data from ADAP Monitoring Reports and Kaiser Family Foundation from 2006 to 2010. We found stricter eligibility requirements reduce the number of HIV-positive individuals with ART access through ADAP, and decreased ART use increases mortality by 2.67 quality-adjusted life years (QALYs) per beneficiary. If the ADAP income eligibility cutoff were decreased by 50 percentage points in each state, 4,626 individuals would lose ART access nationwide. Based on a $22,143 cost/QALY, this policy would save $274 million in health care expenditures (2012 dollars), but result in 12,352 QALYs lost, valued at $1.2 billion. Therefore, states should exercise caution in restricting programs that increase ART access for low-income people living with HIV/AIDS.
© The Author(s) 2015.

Entities:  

Keywords:  HIV and AIDS; access to care; government policy; low income; state policy

Mesh:

Substances:

Year:  2015        PMID: 26537525     DOI: 10.1177/1077558715614479

Source DB:  PubMed          Journal:  Med Care Res Rev        ISSN: 1077-5587            Impact factor:   3.929


  2 in total

1.  Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018.

Authors:  Aaron J Siegler; C Christina Mehta; Farah Mouhanna; Robertino Mera Giler; Amanda Castel; Elizabeth Pembleton; Chandni Jaggi; Jeb Jones; Michael R Kramer; Pema McGuinness; Scott McCallister; Patrick S Sullivan
Journal:  Ann Epidemiol       Date:  2020-04-03       Impact factor: 3.797

2.  Economic benefits of the United States' AIDS drug assistance Program: A systematic review of cost analyses to guide research and policy priorities.

Authors:  Kathleen A McManus; Andrew Strumpf; Amy Killelea; Tim Horn; Auntré Hamp; Jessica Keim-Malpass
Journal:  Prev Med Rep       Date:  2022-08-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.